• Product name

    Anti-ALDH5A1/SSADH antibody [EPR7794]
    See all ALDH5A1/SSADH primary antibodies
  • Description

    Rabbit monoclonal [EPR7794] to ALDH5A1/SSADH
  • Host species

  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC/IF or IP
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human ALDH5A1/SSADH aa 500-600. The exact sequence is proprietary.

  • Positive control

    • Fetal liver and A431 lysates Human liver tissue Mouse kidney tissue
  • General notes



     This product was previously labelled as ALDH5A1


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab129017 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Detects a band of approximately 54 kDa (predicted molecular weight: 57 kDa).
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IP.
  • Target

    • Function

      Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
    • Tissue specificity

      Brain, pancreas, heart, liver, skeletal muscle and kidney. Lower in placenta.
    • Pathway

      Amino-acid degradation; 4-aminobutanoate degradation.
    • Involvement in disease

      Defects in ALDH5A1 are the cause of succinate semialdehyde dehydrogenase deficiency (SSADH deficiency) [MIM:271980]. SSADH deficiency is a rare inborn error in the metabolism of 4-aminobutyric acid (GABA) which leads to accumulation of 4-hydroxybutyric acid in physiologic fluids of patients. The disease is characterized by severe ataxia and by mildly retarded psychomotor development.
    • Sequence similarities

      Belongs to the aldehyde dehydrogenase family.
    • Cellular localization

    • Information by UniProt
    • Database links

    • Alternative names

      • Aldedehyde dehydrogenase 5 family antibody
      • Aldehyde dehydrogenase 5 family member A1 antibody
      • Aldehyde dehydrogenase 5A1 antibody
      • Aldehyde dehydrogenase family 5 member A1 antibody
      • ALDH5A 1 antibody
      • Aldh5a1 antibody
      • mitochondrial antibody
      • Mitochondrial succinate semialdehyde dehydrogenase antibody
      • NAD(+) dependent succinic semialdehyde dehydrogenase antibody
      • NAD(+)-dependent succinic semialdehyde dehydrogenase antibody
      • SSADH antibody
      • SSDH antibody
      • SSDH_HUMAN antibody
      • Succinate semialdehyde dehydrogenase antibody
      • Succinate-semialdehyde dehydrogenase antibody
      see all


    • All lanes : Anti-ALDH5A1/SSADH antibody [EPR7794] (ab129017) at 1/10000 dilution

      Lane 1 : Fetal liver lysates
      Lane 2 : A431 lysates

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 57 kDa
      Observed band size: 54 kDa
      why is the actual band size different from the predicted?

    • ab129017, at 1/100 dilution staining ALDH5A1/SSADH in formalin fixed paraffin embedded Human liver tissue by immunohistochemistry

    • ab129017, at 1/100 dilution staining ALDH5A1/SSADH in formalin fixed paraffin embedded Mouse kidney tissue by immunohistochemistry.

    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD


    This product has been referenced in:

    • Hujber Z  et al. GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas. J Exp Clin Cancer Res 37:271 (2018). Read more (PubMed: 30404651) »
    • Shim BY  et al. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis 28:375-83 (2013). Read more (PubMed: 22847606) »
    See all 2 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab129017.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up